CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors-Reference-Cited by-同舟云学术

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors

Published:2017-03-02 Issue:9 Volume:129 Page:1166-1176
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Hughes Amy¹²³,Clarson Jade¹²,Tang Carine¹,Vidovic Ljiljana¹,White Deborah L.²³,Hughes Timothy P.¹²³,Yong Agnes S. M.¹²³

Affiliation:

1. Department of Haematology, SA Pathology, Adelaide, SA, Australia;

2. Cancer Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia; and

3. School of Medicine, The University of Adelaide, Adelaide, SA, Australia

Abstract

Key Points Increased immune suppressors and PD-1 abrogates effector responses in CML patients at diagnosis. Enhanced net effector immune responses and decreased PD-1 and immune suppressors may promote sustained deep molecular response in CML.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/129/9/1166/1402642/blood745992.pdf

Reference61 articles.

1. Deep molecular response in chronic myeloid leukemia: the new goal of therapy?;Mahon;Clin Cancer Res,2014

2. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study;Ross;Blood,2013

3. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy;Rohon;Eur J Haematol,2010

4. Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment;Humlova,2010

5. Immunomodulatory effects of tyrosine kinase inhibitors;Kreutzman;Int Trends Immun,2013

Cited by 146 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy;Acta Histochemica;2024-10

2. Dynamics and bifurcations in a model of chronic myeloid leukemia with optimal immune response windows;Journal of Mathematical Biology;2024-08-23

3. Prognostic Significance of Regulatory T-Cells and PD-1 + CD8 T-Cells in Chronic Myeloid Leukemia Patients Treated with Generic Imatinib;Indian Journal of Hematology and Blood Transfusion;2024-08-20

4. A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial);International Journal of Hematology;2024-08-13

5. Prognostic Role of Human Leukocyte Antigen Alleles and Cytokine Single-Nucleotide Polymorphisms in Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitor Drugs;Genes;2024-06-02